Weyer Anja, Abele Michael, Schmitz-Hübsch Tanja, Schoch Beate, Frings Markus, Timmann Dagmar, Klockgether Thomas
Department of Neurology, University Hospital of Bonn, Bonn, Germany.
Mov Disord. 2007 Aug 15;22(11):1633-7. doi: 10.1002/mds.21544.
The objective of this study was to test the reliability and validity of the Scale for the Assessment and Rating of Ataxia (SARA) in ataxia patients not suffering from autosomal dominant spinocerebellar ataxia (SCA). To this end, 64 patients with various ataxia disorders or stable cerebellar lesions were rated independently by two investigators. In addition to SARA, the following assessment instruments were applied: ataxia disease stage, Barthel index and part IV (functional assessment) of the Unified Huntington's Disease Rating scale (UHDRS-IV). Eighteen patients were rated twice. Inter-rater and intrarater reliability were very high with ICCs of 0.98 and 0.99. Internal consistency was high indicated by Cronbach's alpha of 0.97. Factorial analysis revealed that the rating results were mainly determined by one major factor with an eigenvalue of 6.34 which explained 52.8% of the variance. SARA score increased with disease stage (P<0.0001) and was closely correlated with Barthel index (r=-0.63, P<0.0001) and UHDRS-IV (r=-0.62, P<0.0001), but only weakly correlated with disease duration (r=0.44, P<0.001). The results suggest that SARA is a reliable and valid measure of ataxia in non-SCA ataxia patients.
本研究的目的是测试共济失调评估与评分量表（SARA）在非常染色体显性遗传性脊髓小脑共济失调（SCA）的共济失调患者中的可靠性和有效性。为此，由两名研究人员对64例患有各种共济失调疾病或小脑病变稳定的患者进行独立评分。除了SARA外，还应用了以下评估工具：共济失调疾病分期、Barthel指数和统一亨廷顿病评定量表第四部分（功能评估，UHDRS-IV）。对18例患者进行了两次评分。评分者间和评分者内信度非常高，组内相关系数（ICC）分别为0.98和0.99。Cronbach's α系数为0.97，表明内部一致性较高。因子分析显示，评分结果主要由一个特征值为6.34的主要因子决定，该因子解释了52.8%的方差。SARA评分随疾病分期增加（P<0.0001），并与Barthel指数（r=-0.63，P<0.0001）和UHDRS-IV（r=-0.62，P<0.0001）密切相关，但与病程仅呈弱相关（r=0.44，P<0.001）。结果表明，SARA是评估非SCA共济失调患者共济失调的可靠且有效的指标。
